Related Experiment Videos
[Critical illness polyneuropathy and myopathy]
1First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University.
Rinsho Shinkeigaku = Clinical Neurology
|May 22, 2004
Summary
Critical Illness Polyneuropathy (CIP) and Myopathy (CIM) cause severe weakness in critically ill patients. Prevention involves minimizing corticosteroid and neuromuscular blocking agent use.
Area of Science:
- Neurology
- Intensive Care Medicine
Context:
- Critical illness frequently leads to Critical Illness Polyneuropathy (CIP) and Critical Illness Myopathy (CIM).
- These conditions result in significant muscle weakness and can necessitate mechanical ventilation.
- CIP is a sensorimotor polyneuropathy often linked to sepsis and organ failure.
Purpose:
- To define and differentiate Critical Illness Polyneuropathy (CIP) and Critical Illness Myopathy (CIM).
- To identify predisposing factors and potential preventative strategies for CIP and CIM.
- To discuss the prognosis associated with these critical illness complications.
Summary:
- Critical Illness Polyneuropathy (CIP) and Myopathy (CIM) are common in critical care settings, causing profound weakness.
- CIP is a sensorimotor neuropathy, while CIM encompasses various myopathies, often associated with corticosteroid and neuromuscular blocker use.
- No specific treatments exist; prevention strategies focus on judicious use of certain medications.
Impact:
- Highlights the significant impact of CIP and CIM on patient recovery and resource utilization.
- Informs clinical practice regarding the prevention and management of these debilitating neuromuscular disorders.
- Emphasizes the importance of medication management in critical care to mitigate neurological complications.